Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Acute Myeloid Leukemia eradication targeting cathepsin g with a dual HLA-restricted TCR

View Full Paper
Ask AI
Bookmark
Share

Authors

LCLuca CelliNMNeda MohammadiZMZulma Magnani

Discussion

Loading...

Member takes

Overview

Adoptive T cell therapy using cathepsin g-specific TCR reduces leukemia burden in acute myeloid leukemia, indicating potential for broader application.

Key Points

  • Complete disease eradication in mouse models after P56-TCR therapy highlights the approach's significance.
  • P56-TCR application led to robust antitumoral activity and favorable safety profile in acute myeloid leukemia treatment.
  • Functional characterization involved cytokine release assessments and CRISPR/Cas9 technology to engineer T cells effectively.
  • Observational analysis reveals cathepsin g as a notable target, supporting further clinical exploration in diverse AML patient populations.

Cite This Study

Celli et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d460https://doi.org/10.1182/blood-2025-2361
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cathepsin-G specific CAR-T cells for the treatment of Acute Myeloid Leukemia 21722025
  2. 2A novel B7-H3-specific binder enables effective CAR T-cell therapy in an Acute Myeloid Leukemia experimental model2025
  3. 3Simultaneous high-throughput identification of myeloid leukemia driver mutation-derived public neoantigens and cognate functional TCRs for TCR-T therapy2025
  4. 4Non-hematotoxic Tim-3/CD70 dual-targeting CAR T cells promote potent anti-leukemia activity against acute myeloid leukemia2025 · 1 citations
  5. 5CRISPR/Cas9-engineered universal CD123/B7-H3 tandem CAR-T cell for the treatment of acute myeloid leukemia.2025 · 3 citations